Haemonetics Strengthens Leadership for Innovation and Operational Excellence in Healthcare Technology
- Haemonetics appoints Dr. Frank Chan as Executive Vice President and Chief Operating Officer to enhance innovation and operations.
- Roy Galvin transitions to Executive Vice President and Chief Commercial Officer, focusing on Global Hospital and plasma sectors.
- The leadership changes aim to strengthen Haemonetics' market presence and commitment to operational excellence in healthcare.
Haemonetics Strengthens Leadership to Drive Innovation and Operational Excellence
Haemonetics Corporation, a leading global medical technology firm, announces significant changes to its Executive Leadership team, designed to bolster innovation and operational excellence within the organization. Effective April 7, 2025, Dr. Frank Chan joins as Executive Vice President and Chief Operating Officer. In his new role, Dr. Chan will oversee vital areas including research and development, regulatory affairs, and global manufacturing and supply chain operations. With over 25 years of experience in the medical device sector, Dr. Chan draws on his background as President of Acute Care & Monitoring at Medtronic plc, where he has a proven track record of delivering innovative healthcare solutions and enhancing patient access worldwide.
Concurrent with Dr. Chan's appointment, Roy Galvin transitions to Executive Vice President and Chief Commercial Officer, taking immediate charge of the Global Hospital business alongside his existing responsibilities in the plasma and blood center sectors. Galvin, who joined Haemonetics in 2022 as President of Global Plasma and Blood Center, brings extensive experience in healthcare technology, having previously scaled businesses in the Neuroscience and Orthopedic markets at Medtronic. His leadership is expected to significantly enhance Haemonetics' market presence and operational capabilities as the company continues to focus on critical healthcare areas.
Chris Simon, President and CEO of Haemonetics, voices strong confidence in the strategic appointments of Dr. Chan and Galvin. He believes that their combined expertise will play a pivotal role in advancing the company's long-term growth strategy. Haemonetics aims to deliver innovative medical solutions that not only improve patient outcomes but also reduce healthcare costs. The company's focus on key markets such as blood and plasma component collection, surgical suites, and hospital transfusion services underscores its commitment to operational excellence in the healthcare sector. This leadership restructuring signifies Haemonetics' dedication to laying a robust foundation for sustained success and propelling the next phase of growth.
In addition to the new leadership appointments, Haemonetics remains focused on expanding its product offerings and enhancing customer satisfaction. The company's strategic initiatives align with its mission to innovate within the healthcare landscape, ensuring that it meets evolving market demands effectively. The integration of experienced leaders into key roles positions Haemonetics for continued success in delivering high-quality medical technologies that cater to the pressing needs of healthcare providers and patients alike.
As Haemonetics embarks on this new chapter, the emphasis on innovation and operational excellence is expected to yield significant advancements in the company's service delivery and product development, reinforcing its standing as a leader in the medical technology industry.
